PDS Biotechnology Corp — Net Income by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/04d87fd3-da54-46fe-91d0-b6484dd80b79/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-34.5M | 2025-01-01 – 2025-12-31 | evidence 0001140361-26-012030 |
| FY 2024 | $-37.6M | 2024-01-01 – 2024-12-31 | evidence 0001140361-25-010717 |
| FY 2023 | $-42.9M | 2023-01-01 – 2023-12-31 | evidence 0001140361-24-016265 |
| FY 2022 | $-40.9M | 2022-01-01 – 2022-12-31 | evidence 0001140361-23-014279 |
| FY 2021 | $-16.9M | 2021-01-01 – 2021-12-31 | evidence 0001140361-22-012244 |
| FY 2020 | $-14.8M | 2020-01-01 – 2020-12-31 | evidence 0001140361-21-009142 |
| FY 2019 | $-7.0M | 2019-01-01 – 2019-12-31 | evidence 0001140361-20-007252 |
| FY 2018 | $-3.8M | 2018-01-01 – 2018-12-31 | evidence 0001140361-20-007252 |
| FY 2017 | $-50.9M | 2017-01-01 – 2017-12-31 | evidence 0001140361-18-011218 |
| FY 2016 | $-38.8M | 2016-01-01 – 2016-12-31 | evidence 0001140361-17-010287 |
| FY 2015 | $-28.1M | 2015-01-01 – 2015-12-31 | evidence 0001140361-16-056994 |
| FY 2014 | $-12.2M | 2014-01-01 – 2014-12-31 | evidence 0001140361-16-056994 |
| FY 2013 | $-6.9M | 2013-01-01 – 2013-12-31 | evidence 0001140361-16-056994 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).